Interleukin 18 - Mural Oncology
Alternative Names: IL-18 - Mural Oncology; Interleukin-18 - Mural OncologyLatest Information Update: 04 Oct 2024
At a glance
- Originator Alkermes plc
- Developer Mural Oncology
- Class Antineoplastics; Immunotherapies; Interleukins
- Mechanism of Action Interleukin 18 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 26 Sep 2024 Mural Oncology announced plans to nominate development candidate for Cancer by the end of 2024
- 26 Sep 2024 Mural Oncology intends to submit an Investigational New Drug (IND) Application to the US FDA in the fourth quarter of 2025
- 09 Apr 2024 Pharmacodynamics data from a preclinical study in Cancer released by Mural Oncology